Balyasny Asset Management’s AstraZeneca AZN Stock Holding History

Balyasny Asset Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-137,550	Closed	-$25.3M	–	2889
2025 Q4	$25.3M	Buy	137,550 +91,900	+201%	+$16.1M	0.03%	605
2025 Q3	$7M	Buy	+45,650	New	+$6.91M	0.01%	1220
2024 Q4	–	Sell	-4,750	Closed	-$740K	–	2727
2024 Q3	$740K	Buy	+4,750	New	+$767K	﹤0.01%	2083
2021 Q1	–	Sell	-68,750	Closed	-$6.87M	–	1749
2020 Q4	$6.87M	Buy	+68,750	New	+$7.28M	0.04%	553
2019 Q2	–	Sell	-450,000	Closed	-$36.4M	–	1466
2019 Q1	$36.4M	Buy	+450,000	New	+$35.5M	0.24%	110
2018 Q2	–	Sell	-21,500	Closed	-$1.5M	–	1775
2018 Q1	$1.5M	Buy	+21,500	New	+$1.49M	0.01%	1080
2017 Q3	–	Sell	-100,000	Closed	-$6.82M	–	1872
2017 Q2	$6.82M	Buy	+100,000	New	+$6.53M	0.03%	656

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Balyasny Asset Management's AZN Position: Q1 2026 in Review

Balyasny Asset Management reduced its AstraZeneca (AZN) stake by 72% in Q1 2026, selling an estimated $75.3M and leaving 148,684 shares worth $29.3M. The position accounts for 0.04% of the portfolio, ranked #536.

Balyasny Asset Management first reported a position in AZN in Q3 2013 and has held it in 31 quarters since. The position peaked at $99.1M in Q4 2025. 1,378 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Balyasny Asset Management held 148,684 shares of AstraZeneca worth $29.3M as of Q1 2026.
Balyasny Asset Management sold 390,506 AstraZeneca shares in Q1 2026, an estimated $75.3M.
AstraZeneca made up 0.04% of Balyasny Asset Management's portfolio in Q1 2026, its #536 holding.
Balyasny Asset Management first reported a position in AstraZeneca in Q3 2013 and has held it in 31 quarters since.
Balyasny Asset Management's AstraZeneca position peaked at $99.1M in Q4 2025.
1,378 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.